Stayble Therapeutics AB (publ) reported earnings results for the third quarter and nine months ended September 30, 2022. For the third quarter, the company reported revenue was SEK 0.034 million. Net loss was SEK 5.88 million compared to SEK 3.02 million a year ago. Basic loss per share from continuing operations was SEK 0.42 compared to SEK 0.22 a year ago.
For the nine months, revenue was SEK 0.257 million. Net loss was SEK 19.97 million compared to SEK 7.53 million a year ago. Basic loss per share from continuing operations was SEK 1.44 compared to SEK 0.54 a year ago.